ࡱ> 56 l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~7#܈ ~~4#܈ ~~8#܈ ~~9#܈ ~~3#܈ ~~83ffff̙̙3f3fff3f3f33333f33&dPURSUANT TO SECTION 13 OR 15d ON Balance Sheet+Income StatementN Cash Flows l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/?? Balance SheetIncome Statement Cash FlowsU } } y } U5      TherapeuticsMD, Inc. 8-K 07/30/2018.&PURSUANT TO SECTION 13 OR 15(d) OF THE (d)Exhibits    Exhibit   Number  Description     fffffX@0 (Press Release from TherapeuticsMD, Inc.,4,dated June 30, 2018, entitled TherapeuticsMD/'Announces Second Quarter 2018 FinancialResults.$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/0}qeY* @ l  <*  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!PURSUANT TO SECTION 13 OR 15d OIncome Statement Cash FlowsU } I;} $ } y} $ } y} $ <                                 TherapeuticsMD, Inc. 8-K 07/30/2018 Balance Sheet June 30, 2018December 31, 2017    (Unaudited)            ASSETS Current Assets:         Cash ~ $  ~ 2O -%Accounts receivable, net of allowance~ bW~ 57/for doubtful accounts of $418,604 and $380,580, respectively Inventory~ r~ ZOther current assets~ Z=~ ! Total current assets~ 2'~ bE!Fixed assets, net~ ڡ~  Other Assets:Intangible assets, net~ F~ 1"Prepaid expenses-long term~ V. -Security deposit~ / ~ r| Total other assets~ "q ~  Total assets~ *(~ Z&"-% LIABILITIES AND STOCKHOLDERS? EQUITYCurrent Liabilities:D l~rM;d| $7 ! " # $ % & ' ( ) * + , - . / 0 1 2 3 4 5 6 7 8 9 : ;  Accounts payable ~ bu  ~  6!.Accrued expenses and other current liabilities!!~ !=U!!!~ !2!&" Total current liabilities""~ "J"""~ "-"#########$Long-term Liabilities:$$$$$$$$%Long-term debt%%~ %0p%%% %-%(& Total long-term liabilities&&~ &0p&&& &-&' Total liabilities''~ 'F~'''~ '-'(((((((((%)Commitments and Contingencies))))))))*********+Stockholders? Equity:++++++++6,.Preferred stock - par value $0.001; 10,000,000,,,,,,,,-shares authorized;*." no shares issued and outstanding.. .-... .-.4/,Common stock - par value $0.001; 350,000,000////////0shares authorized:.1&216,834,059 and 216,429,642 issued and11~ 1 < 111~ 15 1!2outstanding, respectively"3Additional paid-in capital33~ 3s\|333~ 3{34Accumulated deficit44~ 4M444~ 4B3У4'5 Total stockholders? equity55~ 5|555~ 55961 Total liabilities and stockholders? equity6~ 6*(66~ 6Z&"678$9____________________________1:)Created by Morningstar Document Research.0;(http://documentresearch.morningstar.com/< l~r pR* vQD, =PF0*8X> @;;::996666       l  . DM  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!PURSUANT TO SECTION 13 OR 15d O Balance Sheet Cash FlowsU } 0} $ }  } $ }  }  $ } y} $ } y} $ .     TherapeuticsMD, Inc. 8-K 07/30/2018Income Statement       Three Months Ended   Six Months Ended    June 30,   June 30,  ~   ~   ~   ~                 Revenues, net ~    ~ m  ~ J  ~       Cost of goods sold~ F~ )  ~  dB  ~ Q Gross profit~ ~   ~    ~ &Ϥ     Operating expenses:     *"Sales, general, and administration~ J~ |  ~  n   ~  Research and development~ ~   ~  L  ~ N~%Depreciation and amortization~ ~ ?  ~    ~ G$ Total operating expense~ t~ !  ~  rM  ~ Vr      Operating loss~ € ~ VE  ~  :;  ~ zx2     Other income (expense):     Miscellaneous income~ zf~    ~  n'  ~ :Accreted interest -~ ;    -  ~ NxInterest expense~ * -  ~  *   -)! Total other (expense) income~ ~ T   ~  *  ~ A     D7l{o]aHbHf  !"#$%&'()*+,- Loss before taxes  ~ bx   ~ .O   ~ C   ~ C !!!!!!!!!! ! ! ! ! !!!""Provision for income taxes"" "-""" "-"" "  " -" " " "-"########## # # # # ###$Net loss$~ $bx$$~ $.O$$ ~ $ C$ $ ~ $C$%%%%%%%%%% % % % % %%%-&%Net loss per share, basic and diluted&&333333ÿ&&&&& & HzGѿ& & &ɿ&'''''''''' ' ' ' ' '''0((Weighted average number of common shares((~ (ꪦ3(((~ (}0(( ( ~ ( n.3( ( (~ (j/() outstanding*$+____________________________1,)Created by Morningstar Document Research.0-(http://documentresearch.morningstar.com/ L Oe!H|i]5=PF0*8X> @--,,++&&&&&& &&$$$$$$ $$           l  1(`h  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??!PURSUANT TO SECTION 13 OR 15d O Balance SheetIncome StatementU } 0G} $ } } $ } } $ 1                                 TherapeuticsMD, Inc. 8-K 07/30/2018 Cash FlowsSix Months Ended    June 30, 2018    June 30, 2017 , $CASH FLOWS FROM OPERATING ACTIVITIES        Net loss ~ C  ~ C 5 - Adjustments to reconcile net loss to net        0 (cash flows used in operating activities:.& Depreciation of fixed assets~ ~ "63+ Amortization of intangible assets~ ~ ?7 Provision for (recovery of) doubtful accounts~ "R~ *" Share-based compensation~ ~ v=:2 Amortization of deferred financing costs~ . ->6 Changes in operating assets and liabilities:( Accounts receivable~ ^~ JD Inventory~ ~ c)! Other current assets~  ~ ^l% Accounts payable~ b\~ B-% Accrued interest~  -C; Accrued expenses and other current liabilities~ ~ j-%Net cash used in operating activities~ N]~ * ,$CASH FLOWS FROM INVESTING ACTIVITIES Patent costs~ .x~ :" Purchase of fixed assets~ 5~ % Payment of security deposit~ L -Dlu5OT Hs]?sw ! " # $ % & ' ( ) * + , - . / 0 - %Net cash used in investing activities  ~ V   ~ ` !!!!!!!!!,"$CASH FLOWS FROM FINANCING ACTIVITIES""""""""!# Proceeds from term loan##~ #### #-#,$$ Payment of deferred financing fees$$~ $j$$$ $-$+%# Proceeds from exercise of options%%~ %D%%%~ %" %,&$ Proceeds from exercise of warrants&& &-&&&~ &^&1')Net cash provided by financing activities''~ 'h?'''~ '~'(((((((((#)Increase (decrease) in cash))~ )I)))~ )@)!*Cash, beginning of period**~ *2O***~ *V4\*+Cash, end of period+~ +$++~ +u+,-$.____________________________1/)Created by Morningstar Document Research.00(http://documentresearch.morningstar.com/&S@koT.)j=PF0*8X> @R 00//..++++     Root Entry FBook  ~i  !"#$%&'()*+,-./01234